Atlas Trials

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical trial NCT02923739 · TERMINATED

Trial details

NCT number
NCT02923739
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaMalignant Ovarian Brenner TumorOvarian AdenocarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous Adenocarcinoma
Start date
2017-05-05
Primary completion
2022-09-27
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.